THE BLOOD-PLACENTAL BARRIER controls the transfer of nutrients from the maternal to the fetal circulation (11) . The maternal and fetal circulations are separated by chorionic villi consisting of trophoblast cells. The microvillous membrane of trophoblast cells directly contacts the maternal circulation and expresses a variety of transporters that actively transport nutrients such as glucose and amino acids to the fetus (2, 10, 25) . Furthermore, various exogenous compounds are recognized by these transporters and by efflux pumps (e.g., P-glycoprotein) that operate to prevent their accumulation in the fetus (27) .
It has been reported that nonsteroidal anti-inflammatory drugs (NSAIDs), such as salicylic acid, ibuprofen, ketoprofen, and diclofenac, may cause adverse effects such as malformation or constriction of the ductus arteriosus when used during pregnancy (17) . On the other hand, acetylsalicylic acid is administered even to gravidae for the treatment of pregnancy-induced hypertension and preeclampsia (29) . To minimize the risks of NSAIDs to the gravida and fetus, it is important to understand the mechanism of their permeation across the placenta. Although the mechanism has not been investigated in detail, it is expected that NSAIDs would interact with monocarboxylate transporters (MCTs) and/or other organic anion transporters (OATs), since they possess a carboxyl moiety.
MCT-mediated transport is linked to a proton gradient and is inhibited by various short-chain monocarboxylic acids and ␣-cyano-4-hydroxycinnamate (CHC), a classical inhibitor of MCT (7) . Full-length cDNAs of MCT1 ϳ8 have already been cloned (7, 19) . MCT1, -2, and -4 transport endogenous monocarboxylic acids such as lactic acid (pKa 3.86) and pyruvic acid, which are mostly ionized at physiological pH (7) . On the other hand, several exogenous monocarboxylic acids, such as salicylic acid, benzoic acid, and valproic acid, have been reported to be transported in the cells expressing rat MCT1 (26) . Similarly, salicylic acid is expected to be transported by MCTs in humans, although it has not been directly demonstrated whether NSAIDs, including salicylic acid, are substrates of human MCTs or not.
The aim of this study was to clarify the transport properties of NSAIDs across the blood-placental barrier and to investigate the possible contribution of MCTs to the transport of NSAIDs by using BeWo cells, a human choriocarcinoma-derived model cell line of the blood-placental barrier (13) . We carried out uptake experiments using radiolabeled drugs and measured intracellular pH (pH i ) change using a pH indicator, 2Ј,7Ј-bis(2-carboxyethyl)-5(6)-carboxyfluorescein (BCECF). Salicylic acid was employed as a model drug of NSAIDs, and its transport properties were compared with those of L-lactic acid, a typical physiological substrate of MCTs.
MATERIALS AND METHODS
Reagents. [7- 14 C]salicylic acid (44 mCi/mmol) was purchased from American Radiolabeled Chemicals (St. Louis, MO). L-[U- 14 C]lactic acid sodium salts (116 mCi/mmol) were purchased from ICN Pharmaceuticals (Irvine, CA). DIDS, FCCP, p-chloromercuribenzosulfonic acid (p-CMBS), furosemide, probenecid, nigericin, CHC, hexanoic acid, and octanoic acid were purchased from Sigma Chemical (St. Louis, MO). BCECF-AM was purchased from Dojindo (Kumamoto, Japan). All other chemicals were of reagent grade.
Cell culture. BeWo cells were obtained from American Type Culture Collection (Rockville, MD). BeWo cells were cultivated in the nutrient mixture F-12 Ham Kaighn's modification (Sigma Chemical) supplemented with 10% FCS, 50 g/ml streptomycin, and 50 U/ml benzylpenicillin K at 37°C under 95% air-5% CO 2. Cells were grown for 4-6 days, and, after reaching confluency, cells were washed with PBS and harvested by exposure to a trypsin-EDTA solution and passed onto new flasks.
Uptake experiment. In the uptake experiment, BeWo cells were seeded at 2.0 ϫ 10 5 cells/ml, 200 l/well, on a 96-well plate (Becton-Dickinson, Franklin Lakes, NJ) and were cultured for 4 days. Before the uptake experiments, the culture medium was removed and cells were washed with 400 l of prewarmed uptake buffer [20 ]lactic acid at 37 or 4°C. In the concentration dependency and the inhibition studies, each unlabeled compound was added to the test solution containing radiolabeled drug, and the pH was adjusted to the desired value with Tris. To terminate the uptake, test solution was removed by suction, and cells were washed with 400 l of ice-cold uptake buffer. In the inhibition study using a metabolic inhibitor, protonophore, or ionophore, cells were preincubated with the uptake buffer containing 10 mM NaN 3, 50 M FCCP, or 2.5 M nigericin for 10 min. For the quantitation of radiolabeled drugs taken up by cells, cells were dissolved in 3 M NaOH over 4 h and neutralized with 6 M HCl. The radioactivity was determined in 4 ml of Clear-sol I (Nakalai Tesque, Kyoto, Japan) using a liquid scintillation counter (model LS6500, Beckman Instruments, Fullerton, CA). The amounts of cellular protein were measured by the method of Lowry et al. (14) with BSA as a standard, and the mean value was 0.0693 Ϯ 0.0016 mg protein/well. The initial uptake was expressed as the ratio of cells to medium (l ⅐ mg protein Ϫ1 ⅐ time Ϫ1 ) obtained by dividing the radioactivity taken up per amount of cellular protein by the concentration of substrate.
Data analysis. To estimate the kinetic parameters, the initial uptake for 30 s (J; nmol/mg protein) was fitted to Eq. 1, consisting of both saturable and nonsaturable components, by using the nonlinear least-squares regression analysis program MULTI (30)
where C is the concentration of substrate, J max is the maximum uptake rate for the saturable component, Km is the half-saturation concentration (mM), and k d is the first-order rate constant (l ⅐ mg protein Ϫ1 ⅐ 30 s Ϫ1 ). The kinetic parameters in the presence of inhibitor were estimated from the equation that gave the best fit (either Eq. 2, 3, or 4) .
Competitive inhibition was calculated as
Uncompetitive inhibition was calculated as
Noncompetitive inhibition was calculated as
where Ki is the inhibitory constant and I is the concentration of inhibitor.
Measurements of pHi. pHi of BeWo cells was measured using the fluorescent pH indicator BCECF by a dual-excitation ratiometric method. BeWo cells were cultured on glass coverslips for 2 days and were loaded with 2 M BCECF-AM in control buffer (140 mM NaCl, 5 mM KCl, 1.8 mM CaCl2, 0.8 mM MgSO4, 5 mM D-glucose, and 20 mM HEPES adjusted to pH 7.0 with Tris) for Ͼ1 h at 25°C. The coverslips were then washed with control buffer for 5 min and used for experiments. Experiments were normally performed in CO2-and/or HCO 3 Ϫ -free conditions to avoid the reduction of pHi resulting from activation of the CO2/HCO 3 Ϫ exchange mechanism. The coverslips with adherent cells were placed in a superfusion chamber (volume 1 ml) mounted on the stage of an inverted fluorescence microscope (TMD-300; Nikon, Tokyo, Japan) and continuously superfused with control buffer or drug solution (flow rate 1 ml/min). All experiments were performed at 33-34°C. Excitation wavelengths were 440 and 495 nm, and the emitted light at 505 nm was monitored by a photomultiplier (SPEX Industries, Edison, NJ). The ratio of intracellular BCECF fluorescence (405 nm/495 nm) was converted to pH i by using a calibration curve obtained with nigericin (5 M) and high-K ϩ buffer (20 mM HEPES, 140 mM KCl, 1.8 mM CaCl 2, 0.8 mM MgSO4, and 5 mM Dglucose), the pH of which was adjusted to 7.8, 7.4, 6.8, or 6.0 with Tris (21) .
Statistical analysis. Statistical analyses were performed by using Student's t-test or ANOVA. A difference between means was considered to be significant when the P value was Ͻ0.05.
RESULTS
Proton-linked uptake of salicylic acid. To investigate whether salicylic acid is taken up in BeWo cells, we performed uptake experiments. The intracellular accumulation of [ 14 C]salicylic acid at 37°C was greater than that at 4°C and increased with a decrease in the extracellular pH at both temperatures (Fig. 1, A and C) . The initial uptake was reduced by preincubation with 10 mM NaN 3 , a metabolic inhibitor (Fig. 1E) . Similar results were obtained for the uptake of L-[ 14 C]lactic acid (Fig. 1, B, D, and F) . At 37°C and extracellular pH 6.0, the uptakes of [ 14 C]salicylic acid and L-[ 14 C]lactic acid were linear for at least 1 min. The initial bindings were not saturable with regard to the concentration (data not shown) and were ϳ5 and 2 l/mg protein for salicylic acid and L-lactic acid, respectively. Therefore, the inhibitory effects of inhibitors and the concentration dependency of the uptake were analyzed at 30 s.
Next, to examine proton influx during the uptake of salicylic acid, we measured the pH i of BeWo cells using BCECF. When BeWo cells were superfused with control buffer (pH 7.0), the pH i ranged from 7.5 to 7.6 [7. 36 Ϯ 0.037 (SE), n ϭ 16] at steady state (Fig. 2) . Under this condition, addition of salicylic acid decreased the pH i (Fig. 2) , indicating that the uptake of salicylic acid is accompanied by proton influx. A similar result was obtained for L-lactic acid (Fig. 2B) .
Next, we investigated whether pH-dependent uptakes of salicylic acid and L-lactic acid are inhibited by a protonophore, FCCP, using radiolabeled drugs. As shown in Fig. 3 , the initial uptakes of [ 14 C]salicylic acid and L-lactic acid were significantly reduced in the presence of 50 M FCCP. Both initial uptakes were attenuated by only 20ϳ30% under a highly acidic intracellular condition that was attained by preincubation with acidic buffer (pH 6.0) for 10 min compared with those in the case of preincubation at pH 7.4 ( Fig. 3,  insets) . Furthermore, we investigated the effect of the ionophore (K
]salicylic acid and L-lactic acid were also significantly reduced by removing a proton gradient using 2.5 M nigericin (Fig. 3 
, C and D).
These results imply that the uptake of salicylic acid, as well as that of L-lactic acid, is proton gradient dependent.
Concentration dependency of the initial uptake rates. The concentration dependency of the initial uptake of salicylic acid was examined at pH 5.5, 6.0, and 7.4. The Eadie-Hofstee plot and kinetic parameters are shown in Fig. 4 (Fig. 4B) . The uptake consisted of saturable and nonsaturable components and was adequately described by Eq. 1. The insets in Fig. 4 , A and B, show EadieHofstee plots of the saturable components. Both uptakes showed a single saturable component.
Inhibitory effects of various monocarboxylic acids and organic anions on the initial uptake rates.
To compare the characteristics of the pH-dependent uptake of salicylic acid with those of L-lactic acid, we investigated the inhibitory effects of various monocarboxylic acids and organic anions ( Table 2) . Salicylic acid, L-lactic acid, pyruvic acid, other short-chain fatty acids (acetic acid, propionic acid, n-butyric acid), medium-chain fatty acids (hexanoic acid, octanoic acid), valproic acid, and aromatic monocarboxylic acids significantly inhibited the initial uptakes of both [
14 C]salicylic acid and L-[
14 C]lactic acid in a concentrationdependent manner. These compounds tended to inhibit the uptake of L-[
14 C]lactic acid more potently than that of [ 14 C]salicylic acid. Succinic acid, a dicarboxylic acid, did not inhibit initial uptake in either case. Although p-aminohippuric acid, which is a substrate of OATs, inhibited the uptake of L-[
14 C]lactic acid, its potency was weak. Probenecid, which inhibits various OATs, inhibited both initial uptakes, whereas furosemide did not inhibit the uptake of [ 14 C]salicylic acid. These results demonstrate that the uptake of salicylic acid is similar to that of L-lactic acid in terms of the inhibitory properties of monocarboxylic acids.
Inhibitory effects of NSAIDs on the initial uptake rates. We investigated the inhibitory effects of other NSAIDs on the pH-dependent uptake of [ 14 C]salicylic acid. Acetylsalicylic acid (1 mM) only slightly inhibited the uptake of [
14 C]salicylic acid, whereas ketoprofen, ibuprofen, diclofenac, and alclofenac markedly inhibited uptake (Table 3) . Diclofenac was the most potent inhibitor among the tested NSAIDs. Although the pattern of inhibitory properties of these NSAIDs for the uptake of L-[
14 C]lactic acid was similar to that for salicylic acid uptake, the potencies were significantly greater in the former case.
We also investigated the inhibitory effects of NSAIDs from the standpoint of pH i . pH i was decreased by the superfusion of 1 mM diclofenac (Fig. 5, A and B) , the most potent inhibitor of L-[
14 C]lactic acid uptake. Under this condition, additional perfusion of 10 mM salicylic acid resulted in further acidification, which was reversed upon removal of salicylic acid from the perfusate (Fig. 5A) . In contrast, additional perfusion of 10 mM L-lactic acid after diclofenac and salicylic acid did not cause further acidification (Fig. 5, B and C) . Conversely, additional perfusion of salicylic acid (Fig.  5D ) and diclofenac (Fig. 5E ) resulted in further acidification after the acidification induced by L-lactic acid. These results indicate that NSAIDs are potent inhibitors of the uptake of L-lactic acid.
Kinetic analysis of the mechanism of mutual inhibition between NSAIDs and L-lactic acid. Because salicylic acid and L-lactic acid each inhibited their uptake of the other (Table 2) , we investigated the inhibitory kinetics. Eadie-Hofstee plots are shown in Fig. 6 (Fig. 6A) . The uptake of L-lactic acid was concentration dependent, with J max and K m values of 13. (Fig. 6C) . These findings indicate that NSAIDs and L-lactic acid do not share a common transporter.
Effects of MCT inhibitors on the initial uptake rates. Finally, to assess whether proton-linked MCTs are involved in the pH-dependent transport of NSAIDs, we performed further studies using MCT inhibitors, i.e., p-CMBS, CHC, and phloretin, which are classical inhibitors of L-lactic acid transport. These compounds markedly inhibited the initial uptake of L-[ 14 C]lactic acid in a concentration-dependent manner, whereas that of [ 14 C]salicylic acid was hardly inhibited (Table 4) .
We also examined whether CHC attenuates the intracellular acidification induced by L-lactic acid, salicylic acid, and diclofenac. Superfusion of 10 mM CHC (pH 7.0) decreased the pH i and resulted in a steadystate pH of 6.73 Ϯ 0.047 (n ϭ 12, mean Ϯ SE; Fig. 7 ). Under this condition, further addition of 10 mM salicylic acid significantly decreased the pH i in the presence of CHC (Fig. 7A) . In contrast, L-lactic acid (10 mM) only slightly decreased the pH i in the presence of CHC (Fig. 7B) . Diclofenac (1 mM) clearly decreased the pH i in the presence of CHC (Fig. 7C) . Insets: effects of preincubation on the initial uptake rates. BeWo cells were preincubated at pH 6.0 (F) or 7.4 (E) for 10 min. After preincubation, the uptakes were measured at 37°C and pH 6.0 for 30 s. Each point represents the mean Ϯ SE of 3-4 experiments. C and D: BeWo cells were preincubated at 37°C and pH 6.0 for 10 min under each condition as follows:
; ᮀ, uptake buffer containing 140 mM KCl and 2. 
DISCUSSION
In this study, to investigate whether NSAIDs are transferred across the placenta by monocarboxylic acid transporters, we compared the transport properties of salicylic acid and L-lactic acid by using BeWo cells. This is the first report to characterize the transport characteristics of salicylic acid at the human blood-placental barrier. From the results of experiments with radiolabeled drugs, the uptakes of both salicylic acid and L-lactic acid were 1) temperature dependent and NaN 3 sensitive, 2) FCCP and nigericin sensitive, and 3) concentration dependent. Moreover, the measurement of pH i revealed that both drugs decreased the pH i of BeWo cells. These findings suggest that salicylic acid and L-lactic acid are taken up in BeWo cells via protonlinked active transport systems.
Transport pathway of L-lactic acid. Various monocarboxylic acids, and well-known inhibitors of lactate transport (p-CMBS, CHC, phloretin; see Ref. 18 ), inhibited the uptake of L-lactic acid by BeWo cell. The K m value for the uptake of L-lactic acid was estimated to be 2ϳ5 mM, which coincided well with the values reported in Xenopus laevis oocytes expressing human MCT1 and MCT2 (6.0 and 6.5 mM, respectively; see Ref. 12). We also revealed that mRNA of MCT1, -3, -5, -6, and -7 are expressed in BeWo cells by using RT-PCR and DNA sequencing (data not shown). Thus we conclude that the uptake of L-lactic acid into BeWo cells is mediated by MCT, although the problem of which MCT(s) transports L-lactic acid should be solved in the future by using the expression system. Interestingly, the initial uptake of L-[ 14 C]lactic acid was activated by preincubation with uptake buffer (Fig. 1, B and F) , but this phenomenon was not the case for salicylic acid (Fig. 1, A and E) . A speculative explanation for this phenomenon is that lactate efflux occurred during preincubation and its intracellular concentration became low, so lactate was easily taken up in the cells.
Proton influx was directly demonstrated by measurement of pH i under an inwardly directed proton gradient. The pH i was further decreased by superfusion of L-lactic acid (Fig. 2B) , indicating that influx of proton into BeWo cells accompanied that of L-lactic acid. This proton influx was largely suppressed by CHC (Fig. 7B) . The portion of L-lactic acid-induced acidification that was resistant to CHC may be accounted for the concentration of substrate used in this study; we used 10 mM L-lactic acid to allow clear detection of the change in pH by BCECF, and, at this concentration, the nonsaturable component is estimated to amount to 40-50% of total uptake (Table 1) . Thus the aforementioned decrease in the pH i may result from a pathway independent of the proton gradient, such as the passive diffusion of protonated lactic acid. 14 C]lactic acid). Results are the relative total uptake and the relative saturable uptake to the value in the absence of acids (control values: 3 M L-lactic acid, 10.6 Ϯ 0.55 l; 1 mM L-lactic acid, 15.7 Ϯ 0.30 l; 6 M salicylic acid, 26.4 Ϯ 1.54 l; 1 mM salicylic acid, 16.2 Ϯ 0.78 l). Saturable uptake was calculated by subtracting the nonsaturable component from total uptake. Significant difference from the control was determined by using ANOVA followed by Duncan's test ( † P Ͻ 0.01).
Measurement of pH i also revealed that CHC itself potently decreased the pH i (Fig. 7) . This finding is consistent with the fact that CHC competitively inhibits the transport of lactate (6) . Therefore, at least in BeWo cells, CHC may be transported by MCT and also may competitively inhibit MCT.
Transport pathway of NSAIDs. Various monocarboxylic acids specifically inhibited the uptake of salicylic acid into BeWo cells. In this respect, salicylic acid and L-lactic acid share similar characteristics. On the other hand, L-lactic acid-induced intracellular acidification was strongly attenuated by preincubation with salicylic acid (Fig. 5C) or diclofenac (Fig. 5A ), but not vice versa (Fig. 5, D and E) . These findings suggest that NSAIDs and L-lactic acid are transported by distinct pathways. However, this seems to be inconsistent with the result that the uptake of salicylate was inhibited by lactate competitively (Fig. 6A) . This discrepancy might be caused because the affinity of lactate to salicylate transporter was quite low, with a K i value of 45 mM. The value is quite high compared with the physiological concentration of lactate (Ͻ10 mM), and we did not use such a high concentration in this study. Thus, under the current experimental concentration range, the component of lactate transport by salicylate transporter may overlap with the nonsaturable component, and it might not be detected at the concentration used in this study.
The difference between the pathway of L-lactic acid and salicylic acid could be classified in terms of the sensitivity to CHC. In other words, L-lactic acid was transported mainly via a pathway sensitive to CHC, whereas the NSAIDs were transported via a protonlinked pathway insensitive to CHC (Fig. 8) . Indeed, the uptake of salicylic acid was not inhibited by CHC or other MCT inhibitors, which potently inhibited the uptake of L-lactic acid (Table 4) . Correspondingly, in the measurement of pH i , CHC did not attenuate the decrease in pH induced by 10 mM salicylic acid, a concentration at which the saturable component was estimated to amount for 85% of total uptake (Table 1 and Fig. 4) . Therefore, the saturable component of the uptake of salicylic acid is considered not to be strongly suppressed by CHC. This is remarkably different from the case of L-lactic acid uptake. With regard to diclofenac, we only performed a measurement of pH i , since radiolabeled diclofenac was not available; hence, we could not directly investigate uptake. The intracellular acidification induced by diclofenac (1 mM; Fig. 5 ), which implies that diclofenac was taken up with protons in BeWo cells, was not suppressed by CHC (10 mM; Fig. 7C ). Thus diclofenac may also be transported via the CHC-insensitive pathway, as well as salicylic acid (Fig. 8) .
Inhibitory character of NSAIDs on the uptake of L-lactic acid. In this study, several NSAIDs potently inhibited the uptake of L-[ 14 C]lactic acid (Table 3) . These results are consistent with previous reports that diclofenac (0.05 mM) inhibited the Na ϩ -dependent and pH-independent transport of lactate by 85% in pigmented rabbit conjunctiva and that ibuprofen (5 mM) . Saturable uptake was calculated by subtracting the nonsaturable component from total uptake. Significant difference from the control was determined by using ANOVA followed by Duncan's test ( † P Ͻ 0.01).
inhibited the pH-dependent transport of lactate by 70% in Caco-2 cells (8, 15) .
It is not yet known whether these NSAIDs share common transporters with L-lactic acid. Therefore, there are two possible explanations for the inhibitory effects of NSAIDs on the uptake of L-lactic acid. One possibility is that NSAIDs directly inhibit lactate transporters. The other possibility is that the proton gradient (the driving force for lactate transporters) is attenuated by the proton-linked influx of NSAIDs, resulting in a decrease in the uptake of L-lactic acid. However, the initial uptake of L-[
14 C]lactic acid was only attenuated by 20-30% under a highly acidic intracellular condition attained by preincubation with acidic buffer (pH 6.0) for 10 min, compared with the case of preincubation at pH 7.4 (Fig. 3, A and B; insets) . Under this experimental condition, components insensitive to nigericin, which removes the transmembrane proton gradient, remained (Fig. 3, C and D) . These results indicate that intracellular acidification alone is not sufficient to suppress the uptake of L-lactic acid. Therefore, it is conceivable that salicylic acid and diclofenac may directly inhibit the lactate transport system.
Nature of the CHC-insensitive pathway. The CHCinsensitive transport system was demonstrated to play an important role in NSAID transfer across the bloodplacental barrier. The candidates for transporters of salicylic acid are MCTs, anion exchanger, and OATs. Several studies have been conducted to investigate whether MCT is involved in the transport of salicylic acid. Tamai et al. (26) reported that, in rat MCT1-expressing cells, salicylic acid is transported by rat MCT1, along with L-lactic acid and benzoic acid. Utoguchi et al. (28) showed that, in BeWo cells, the uptake of L-lactic acid was competitively inhibited by benzoic acid, an aromatic monocarboxylic acid similar to salicylic acid. However, in this study, inhibition of the uptake of L-[ 14 C]lactic acid by salicylic acid was noncompetitive (Fig. 6 ). In addition, differences in the sensitivity to MCT inhibitors were demonstrated (Table 4). On the basis of these results, salicylic acid may not be a substrate of human MCT, or it may have a quite low affinity for MCT as a substrate, even though it is a potent inhibitor. It was also reported that L-lactic acid has different affinities for each MCT isoform and that each MCT isoform has a different pattern of sensitivity to MCT inhibitors (CHC, phloretin, and p-CMBS; see Refs. 5, 7, and 20) . Because MCT1 and -4 are sensitive to CHC, salicylic acid may be a substrate of some other MCT isoform(s) expressed in BeWo cells.
With regard to the involvement of an anion exchanger, it has been reported that both lactic acid and salicylic acid are transported by anion exchangers, . Results are the relative total uptake and the relative saturable uptake to the value in the absence of inhibitor (control values: 3 M L-lactic acid, 14.5 Ϯ 0.14 l; 1 mM L-lactic acid, 5.37 Ϯ 0.12 l; 6 M salicylic acid, 26.5 Ϯ 0.36 l; 1 mM salicylic acid, 22.6 Ϯ 0.36 l). Saturable uptake was calculated by subtracting the nonsaturable component from total uptake. Significant difference from the control was determined by using ANOVA followed by Duncan's test ( † P Ͻ 0.01).
which are sensitive to DIDS and activated by a HCO 3 Ϫ gradient (16) . However, we performed experiments under HCO 3 Ϫ -free conditions in this study, so the contribution of this anion exchanger may be neglected under our conditions.
Last, a few reports have also been demonstrated that NSAIDs are transported or interacted with OAT. Apiwattanakul et al. (1) and Sekine et al. (22) demonstrated by using rat OAT1-and rat OAT2-expressing X. laevis oocytes that salicylic acid was a substrate of both transporters. However, human OAT1, -2, -3, and -5 mRNA, except for OAT4, were little expressed in placental tissue by Northern hybridization (9, 24) . Although human OAT4 is expressed, salicylate has been reported not to inhibit the uptake of [ 3 H]estrone sulfate by OAT4-expressed oocytes (3). Moreover, there has been no report indicating that OATs are dependent on a proton gradient. Therefore, the involvement of OATs in the pH-dependent transport of salicylic acid is unlikely.
Permeation through placenta and exposure to the fetus. Kinetic analysis revealed that a portion of the saturable component is ϳ50% at the therapeutic plasma concentration of salicylic acid (ϳ100 M; see Table 1 ), showing that the nonsaturable component is also substantial. It may be possible that the bloodplacental barrier may be not so tight for the permeation of salicylate. On the other hand, assuming that extracellular pH is 7.0-7.3, the saturable component of initial uptake of salicylic acid seems to be much larger ( Fig. 3 and Table 1 ). Indeed, the microacidic environment is formed by an Na ϩ /H ϩ antiporter that is localized on the brush-border membrane of BeWo cells (23) .
Therefore, it should not be definitely concluded that the uptake of salicylate by active transporters is not significant in the exposure and/or the adverse effects to the fetus, although the contribution of the nonsaturable component was first determined quantitatively in this study. To fully understand the transplacental transfer of salicylic acid, the transfer from trophoblast cells to the fetus and subsequent steps should be taken into consideration in addition to the transfer across trophoblast cells that we investigated here.
In conclusion, NSAIDs potently inhibited the transport of L-lactic acid across BeWo cells. However, the transport system of NSAIDs is essentially CHC insensitive and apparently is different from that of L-lactic acid.
